Jean‐François Rahier

Author

Also Known As

Camille Zallot, D Franchimont, Edouard Louis, European COMBIO study group, J -F Rahier, J F Rahier, J RAHIER, J Rahier, J. -F. Rahier, J. F. Rahier

151

Publications

6.6K

Citations

H-Index

Concepts

All Affiliations

CHU Dinant Godinne UCL Namur UCLouvain KU Leuven Icahn School of Medicine at Mount Sinai Imelda Hospital

About

Jean‐François Rahier is an author at CHU Dinant Godinne UCL Namur specializing in medicine, immunology, and gastroenterology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	1.5K
2	Public Health	2	3	143
3	Cell Biology	2	2	154
4	Allergy	1	1	38
5	Biochemistry	1	1	38

Jean‐François Rahier

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease Jean‐François Rahier, Fernando Magro, Cândida Abreu, Journal of Crohn s and Colitis	2014	909
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry Erica J. Brenner, Ryan C. Ungaro, Richard B. Gearry, Gastroenterology InflammationAnti-inflammatoryInternational RegistryImmunologyGastroenterology	2020	687
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease Lysiane Marthey, Christine Mateus, Charlotte Mussini, Journal of Crohn s and Colitis	2016	335
Effect of IBD medications on COVID-19 outcomes: results from an international registry Ryan C. Ungaro, Erica J. Brenner, Richard B. Gearry, Gut	2020	279
IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes Yukihide Momozawa, Julia Dmitrieva, Emilie Théâtre, Nature Communications	2018	238
Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study María Chaparro, A Verreth, Triana Lobatón, The American Journal of Gastroenterology	2018	167
Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Anti–Tumor Necrosis Factor Therapy Jean‐François Rahier, S. Buche, Laurent Peyrin‐Biroulet, Clinical Gastroenterology and Hepatology InflammationAutoimmune DiseaseSurgical PathologyImmunologyChronic Inflammation	2010	165
Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti‐TNF or conventional therapy: results of the European CONCEIVE study Annick Moens, C. Janneke van der Woude, Mette Julsgaard, Alimentary Pharmacology & Therapeutics	2019	133
The Multiple Sclerosis Genomic Map: Role of peripheral immune cells and resident microglia in susceptibility NA Patsopoulos, Sergio E. Baranzini, Adam Santaniello, Resident MicrogliaInnate Immune SystemImmunologyInnate ImmunityImmune System	2017	116
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn’s Disease Who Failed Biologic Therapies: A National Cohort Study Claire Liefferinckx, Bram Verstockt, Ann Gils, Journal of Crohn s and Colitis	2019	114

Page 1